-
Mashup Score: 0Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials - 26 day(s) ago
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas - 29 day(s) ago
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence - 1 month(s) ago
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence after surgical resection.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer - 1 month(s) ago
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced, unresectable vulvar squamous cell carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
According to Neil Horowitz, MD, and coauthors, "compared with historic results, the addition of gemcitabine to cisplatin once per week given concurrently with [intensity-modulated RT] significantly improved the [pCR]." Learn more: https://t.co/aSZNAGXIiY #medtwitter #onctwitter https://t.co/4A9aDPWVOZ
-
-
Mashup Score: 2The Benefit of Perioperative Immunotherapy in Lung Cancer Treatment - 1 month(s) ago
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Supremacy of Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer - 1 month(s) ago
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL - 1 month(s) ago
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma - 1 month(s) ago
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF V600 mutation.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors - 1 month(s) ago
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients age 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
Discover insights on chronic lymphocytic leukemia (CLL) treatment with our new sponsored video. Learn about updates for a treatment option for CLL. #CLL #Oncology #leukemia #videoresources #onlinelearning #virtualeducation https://t.co/I4rpPwRpNm https://t.co/R4YE5jBi0Y